Ipsen Biopharmaceuticals To Present Further Data On Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), At Gastrointestinal Cancers Symposium

Ipsen Biopharmaceuticals Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY) today announced three presentations of lanreotide data to be shared at the 2015 Gastrointestinal Cancers Symposium, January 15-17, 2015 in San Francisco, CA. One oral and two poster presentations will explore the use of lanreotide in gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), including sub analyses of the pivotal Phase III, multinational, randomized, double-blind clinical trial (CLARINET®).

Help employers find you! Check out all the jobs and post your resume.